Low-Dose rituximab shows promise for blood disorder
NCT ID NCT01719692
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition causing low platelet counts and bleeding. The goal was to see which regimen better raises platelets and controls bleeding. Participants had failed or relapsed on standard steroid therapy. The trial compared weekly low doses versus a single higher dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of Blood disease
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Double attack on blood disorder: could two drugs beat one for stubborn ITP?
- Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
- New hope for lupus patients with dangerous low platelet counts
- Can a simple blood test predict who will get chronic ITP?
- New shot aims to boost platelets in bleeding disorder